Cutaneous eruptions from ibrutinib resembling epidermal growth factor receptor inhibitor–induced dermatologic adverse events

Singer, Sean; Tan, Sally; Dewan, Anna K.; Davids, Matthew S.; LaCasce, Ann S.; Treon, Steven P.; LeBoeuf, Nicole R.

doi:10.1016/j.jaad.2019.12.031

Cited by 29 publications

(49 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present paper, a single‐centre experience in a real‐life setting has been provided. To the best of our knowledge, we have provided the largest series available 14,20 . As observed by Singer et al and Yorulmaz et 20,24 most of the Ibrutinib SAEs involved the nails and hair (Figure 1 a‐c, Figure 3 b‐d), reinforcing the hypothesis that Ibrutinib may have off‐target activity against EGFR in the skin 20,24,25 .…”

Section: Discussionsupporting

confidence: 71%

“…We can hypothesize whether those lesions should be considered as an initial stage of cutaneous vasculitis, which may have auto‐limited without any treatment changes. In our series, we neither observe a photosensitive reaction, recently reported by other authors 20 nor an acneiform/pustular rash. A possible explanation for the former AE may be the recommended application of photoprotector after Ibrutinib start as well as strict sun avoidance.…”

Section: Discussioncontrasting

confidence: 64%

“…To the best of our knowledge, we have provided the largest series available. 14,20 As observed by Singer et al and Yorulmaz et 20,24 most of the Ibrutinib SAEs involved the nails and hair (Figure 1 a-c, inhibitor Selumetinib. 27 Unlike Bitar et al, 18 no onycorrhexis was observed in our patients, while nail involvement developed earlier (6.5 months vs 160 days).…”

Section: Discussionmentioning

confidence: 61%

“…As Ibrutinib is becoming commonly used in the hematological setting clinicians ought to be familiar with its therapeutic and side‐effects. Apart from the experience of two American groups, 14‐20 descriptions on Ibrutinib AE are limited to a few case reports 15‐19,22‐24 . In the present paper, a single‐centre experience in a real‐life setting has been provided.…”

Section: Discussionmentioning

confidence: 99%

“…Despite such relatively promising scenarios little is known about the adverse events of the drug, and in particular on the skin sideeffects (SAE). Apart from two single-centre experiences, only single case-reports are present in the literature [14][15][16][17][18][19][20] . The aim of our paper is to expand our knowledge on Ibrutinib SAE by providing a singleinstitution experience.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Cutaneous adverse‐events in patients treated with Ibrutinib

Pileri

Guglielmo

Agostinelli

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

Ibrutinib is a Burton tyrosine kinase inhibitor (BTKi) approved for the treatment of several hematologic malignancies. Analyze skin adverse events (SAE). All the patients treated with Ibrutinib featuring cutaneous adverse events were selected. Twenty five patients were retrieved with a median interval between Ibrutinib start and SAE time of onset of 120 days. Most common SAE observed involved hairs and nails. Eczematous reaction and leucocytoclastic vasculitis were also detected. One patient had a long-history Ibrutinib treatment and experienced numerous cutaneous adverse events. Infective disease such as superficial mycosis and impetigo were rarely present in our series. Despite the development of cutaneous SAE, all the patients continued their concomitant drugs without the onset of any further SAE. Our data suggest Ibrutinib-associated rash should be distinguished in early and late events and a careful dermatologic management of patients should be scheduled.

show abstract

Section: Discussionsupporting

confidence: 71%

Section: Discussioncontrasting

confidence: 64%

Section: Discussionmentioning

confidence: 61%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Cutaneous adverse‐events in patients treated with Ibrutinib

Pileri

Guglielmo

Agostinelli

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

Asymptomatic Purpuric Eruption on the Scalp of a Middle-aged Man

Mohammed

Patel

2021

JAMA Oncol

View full text Add to dashboard Cite

A man in his 60s presented to the clinic with a several-day history of nontender, nonitchy purpuric rash on his scalp. The patient denied using any over-the-counter or prescription topicals at the affected sites before the onset of the eruption except for petroleum jelly. His medical history was significant for chronic lymphocytic leukemia (CLL) and allergic contact dermatitis. The patient reported being started on ibrutinib and allopurinol therapy 6 weeks prior to the rash onset for treatment of CLL. Physical examination revealed multiple purpuric, nonblanchable macules and patches on the frontal, vertex, temporal, and parietal scalp (Figure , A). A punch biopsy specimen from the scalp was obtained for histopathologic analysis (Figure , B).

show abstract

Strategies for overcoming resistance to Bruton's tyrosine kinase inhibitor zanubrutinib

Dostálová,

Kryštof

2024

Hematological Oncology

View full text Add to dashboard Cite

Bruton's tyrosine kinase (BTK) inhibitors have revolutionized the treatment of B‐cell malignancies. They target BTK, a key effector in the B‐cell receptor (BCR) signaling pathway, crucial for B‐cell survival and proliferation. The first‐in‐class irreversible BTK inhibitor, ibrutinib, was approved for various B‐cell malignancies but has limitations due to off‐target effects. Second‐generation inhibitors, such as acalabrutinib and zanubrutinib, offer improved selectivity and reduced side effects. However, resistance to BTK inhibitors, driven by BTK mutations, remains a challenge. Combinatorial therapies with PI3K inhibitors, immune checkpoint inhibitors, BH3 mimetics, and anti‐CD20 antibodies show promise in overcoming resistance. Noncovalent BTK inhibitors and proteolysis‐targeting chimeras (PROTACs) are emerging strategies with potential to combat resistance. Overall, advancements in BTK‐targeted therapies provide hope for improved outcomes in patients with B‐cell malignancies and a promising avenue to address drug resistance. Further research is needed to optimize combination therapies and identify optimal treatment regimens.

show abstract

Cutaneous eruptions from ibrutinib resembling epidermal growth factor receptor inhibitor–induced dermatologic adverse events

Cited by 29 publications

References 17 publications

Cutaneous adverse‐events in patients treated with Ibrutinib

Cutaneous adverse‐events in patients treated with Ibrutinib

Asymptomatic Purpuric Eruption on the Scalp of a Middle-aged Man

Strategies for overcoming resistance to Bruton's tyrosine kinase inhibitor zanubrutinib

Contact Info

Product

Resources

About